肺癌和双重向药物治疗中的HIF-1α和EZH2之间的相互作用
Jianmin Wang1,2, Cheng Yang1,2, Huashen Xu3
1School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, 110016, P. R. China.
这项研究揭示了增强体同源2 (EZH2) 的增强剂在肺癌中介于对低氧诱导因子 (HIF-1) 抑制剂的抵抗. 一种新型化合物,DYB-03,针对HIF-1和EZH2,显示出组合疗法的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 瘤原蛋白相互作用驱动癌症表型和耐药性.
- 增强剂的zest同源2 (EZH2) 涉及到调解耐低氧诱导因子 (HIF-1) 抑制剂的耐药性.
研究的目的:
- 阐明EZH2和HIF-1之间交叉调节的分子机制.
- 评估一种新型双标化合物DYB-03在肺癌中的治疗潜力.
主要方法:
- 研究了EZH2和HIF-1之间的转录调节.
- 利用分子预测来设计DYB-03.
- 使用肺癌细胞系,HUVEC和异种移植模型进行了体外和体内研究.
- 评估了对2-ME2和GSK126.6药物耐药性的逆转.
主要成果:
- 针对HIF-1可以通过SUZ12.2增强EZH2活动.
- 抑制EZH2增加了HIF-1α转录,表明了负反.
- DYB-03有效地抑制HIF-1α和EZH2,抑制肺癌细胞迁移,入侵和血管生成.
- 在体内,DYB-03通过促进亡和抑制血管生成,依赖于HIF-1α和EZH2.2,表现出抗瘤活性.
- 在肺癌中,DYB-03可以逆转对2-ME2和GSK126的耐药性.
结论:
- 确定了HIF-1α和EZH2交叉调节的分子机制.
- 通过向HIF-1和EZH2.2,DYB-03显示出作为肺癌临床组合治疗药物的潜力.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Regulation of Angiogenesis and Blood Supply
Mitogens and the Cell Cycle
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
